TP53 mutations on circulating cell-free DNA
نویسنده
چکیده
Article history: Received 6 July 2016 Accepted 6 July 2016 Available online 8 July 2016 Besides the demand for higher sensitivity, the specificity of cfDNA measurements faces even more serious challenges. Cancer-associated mutations are thought to be restricted to cancer patients. However, Fernandez-Cuesta et al. observed cfDNA TP53-mutated fragments in 11.4% of 123 matched non-cancer controls. Acknowledging the potential for bias in the selection of controls (such as differential performance
منابع مشابه
Detection of Mutations in Exons 5 and 8 of Tumor Suppressor Tp53 Gene in Patients with Squamous Cell Carcinoma of Lung Hospitalized in Afzalipour Hospital, Kerman, Iran
Introduction: Despite improvements in the diagnosis and treatment of lung cancer in the past two decades, it has remained the most common cause of death from cancer worldwide. Among all genes that are mutated in lung cancer, TP53 located on chromosome 17P13/1 has a significant diagnostic and prognostic value. TP53 mutations have been extensively studied in lung cancer and TP53 mutational spectr...
متن کاملIdentification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer
Circulating tumor DNA (ctDNA) is emerging as a key potential biomarker for post-diagnosis surveillance but it may also play a crucial role in the detection of pre-clinical cancer. Small-cell lung cancer (SCLC) is an excellent candidate for early detection given there are no successful therapeutic options for late-stage disease, and it displays almost universal inactivation of TP53. We assessed ...
متن کاملTP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
In tumours that harbour wild-type p53, p53 protein function is frequently disabled by the mouse double minute 2 protein (MDM2, or HDM2 in humans). Multiple HDM2 antagonists are currently in clinical development. Preclinical data indicate that TP53 mutations are a possible mechanism of acquired resistance to HDM2 inhibition; however, this resistance mechanism has not been reported in patients. U...
متن کاملDetection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful tool for the detection/monitoring of alterations present in circulating tumor DNA (ctDNA). Plasma extracted from 171 patients with a variety of cancers was analyzed for ctDNA (54 genes and copy number variants (CNVs) in three genes (EGFR, ERBB2 and MET)). The most represented cancers were lung (23%), breast (23%), an...
متن کاملCirculating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches
The use of non-invasive biomarkers such as circulating tumor DNA (ctDNA) in head and neck tumors may be of relevance in early diagnosis and eventually improved outcome. We evaluated two different approaches from two case series in Europe and South America including (i) targeted screening of ctDNA mutations, and (ii) detection of TP53 mutations in plasma and oral rinses without previous knowledg...
متن کامل